A Phase 1/2 interventional study of KRT-232 and Dasatinib in Chronic Myeloid Leukemia, sponsored by Kartos Therapeutics, Inc.. Recruiting at 26 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-03-21.
Sponsored by Kartos Therapeutics, Inc. (part of Ipsen) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 517 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States — 46 open to participants now, 77 under way, 4 of them phase 3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive · United States.
Among the 517 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States, this one is the 86th largest by planned enrollment of the 449 interventional ones that give a count, is one of 14 that started in 2021, is one of 55 in phase 1/2, reaches primary completion later than 10 of the 76 other live ones, and was the 461st registered.
895 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 105 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →46 of the 517 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States are open now. Recruiting first, the newest first:
Enliven Therapeutics · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 18+
National Cancer Institute (NCI) · Sites in United States
Ages 18–120
University of Arizona · Sites in United States
Ages up to 65
Stanford University · Sites in United States
Ages 18–80
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 75 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 46 (61%) set no upper age limit and 19 (25%) stop at 75 or younger; 19 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
517 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 173 · Phase 2 277 · Phase 3 32 · Phase 4 7
First in 1992; this study’s year is marked. 14 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 109 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 36 across the 449 interventional studies, 142 across the 44 observational. Of the 409 that completed or were terminated, 195 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
128 of 517 have an industry lead sponsor. The 10 most frequent:
This study is registered under Kartos Therapeutics, Inc., one of the names counted as Ipsen. Under that name alone:
Kartos Therapeutics, Inc. is the lead sponsor of 16 studies on the registry; 7 are open to participants now.
Ipsen has 1 study filed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive — fewer than ten, so there is no comparison to draw.
22 of the studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06423911Phase 3Ascentage Pharma Group Inc.Study of Olverembatinib (HQP1351) in Patients With CML-CP | 2027-06-30 |
| NCT05362773MacroGenicsA Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | 2026-11 |
| NCT01890486Wake Forest University Health SciencesThe Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen | 2026-12 |
| NCT06131801Children's Hospital Medical Center, CincinnatiPharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution | 2026-12-01 |
| NCT06001385Center for International Blood and Marrow Transplant ResearchHLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis | 2026-12-24 |
Add all 22 to your calendar (.ics) → With an account.
Among the 517 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia (CML) who have relapsed or are refractory or intolerant to a Tyrosine Kinase Inhibitor (TKI).
This study is a global, open label Phase 1b/2 to determine the efficacy and safety of KRT-232 in patients with chronic phase CML (CML-CP) and accelerated phase (CML-AP) who have failed TKI treatments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. TKI (dasatinib or nilotinib) will be administered orally, per locally prescribed dose and schedule.
Drug: KRT-232 · Drug: Dasatinib · Drug: Nilotinib
KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Dasastinib will be administered orally, per locally prescribed dose and schedule.
Drug: KRT-232 · Drug: Dasatinib
KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Nilotinib will be administered orally, per locally prescribed dose and schedule.
Drug: KRT-232 · Drug: Nilotinib
KRT-232 will be administered orally, once daily (QD) on Days 1-7 in a 28-day cycle. Dasatinib or Nilotinib will be administered orally, per locally prescribed dose and schedule.
Drug: KRT-232 · Drug: Dasatinib · Drug: Nilotinib
KRT-232 is an experimental MDM2 inhibitor anticancer drug taken by mouth.
Dasatinib is a Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
Also known as: Dasatinib Zentiva
Nilotinib is an Tyrosine Kinase Inhibitor anticancer drug taken by mouth.
Also known as: Tasigna
Part 1: Maximum tolerated dose (MTD)/maximum administered dose (MAD) of KRT-232
DLTs will be used to establish the MTD/MAD of KRT-232 in combination with dasatinib or nilotinib
Time frame: 28 Days
Part 2, Arm A and B: Major molecular response (MMR) rate
The proportion of subjects who achieved complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR) according to modified ELN criteria
Time frame: 6 months
Part 2, Arm C: Major hematological response (MaHR) rate
The proportion of subjects who achieved MaHR according to modified ELN criteria
Time frame: 6 months
CCyR rate
The proportion of subjects who achieved CCyR or PCyR according to modified ELN criteria in Arms A and B
Time frame: 12 months
MCyR rate
The proportion of subjects who achieved CCyR or PCyR according to modified ELN criteria in Arm C
Time frame: 47 months
Duration of response
DOR (Kaplan-Meier estimate) defined as the time from first observation of response to progression/relapse or death, whichever comes first
Time frame: 47 months
Rate of complete hematologic response (CHR)
The proportion of subjects who achieve a CHR according to modified ELN criteria in Arms A and B
Time frame: 47 months
Progression-free survival (PFS) in each Arm
PFS is defined as the time from the first treatment dose date to progression/relapse or death, whichever comes first
Time frame: 47 months
Overall survival (OS) in each Arm
OS is defined as the time from the first treatment dose date to death from any cause
Time frame: 47 months
Started May 2021 (actual). Primary completion is estimated for Dec 2024, 43 months after the start.
Of 27 phase 1/2 interventional studies under Leukemia, Myelogenous, Chronic, BCR-ABL Positive, half reached primary completion within 69 months of starting (the median), counting those still running; a quarter within 56 and three quarters within 94. This study's planned 43 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →